You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?

Name: You have identified the challenges of accessing PCSK9 inhibitors for patients whose CV risk is genetic vs. those whose clinical course is characterized by progressive vascular events. How do you approach each subset with respect to LDL-C management?
Uploaded: 2019-03-17T00:00:00+00:00

Get Credit

Created by

Presenter

Paul Ridker, MD

Atherosclerosis Prevention
Paul Ridker, MD,
Eugene Braunwald Professor
Harvard Medical School
Division of Cardiovascular Medicine
Director, Center for Cardiovascular Disease Prevention
Brigham and Women’s Hospital
Boston, MA